long intergenic non-protein coding RNA 2050Genealiases: []
Q-omics provides the consensus-scored LINC02050 profile across patient tissues and cancer cell-line models. LINC02050 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC02050 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, LINC02050 RNA expression shows 6,352 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, LIHC, and TGCT as cancer lineages where LINC02050 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02050 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02050 survival associations across molecular data types. LINC02050 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02050 RNA expression–survival associations across cancer types. High LINC02050 expression shows unfavorable associations in HNSC, ACC, OV, KICH and KIRP, but favorable associations in SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC02050 RNA expression.
This table summarizes LINC02050 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02050. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02050 shows higher tumor expression in LIHC and PRAD. The LIHC box plot shows higher LINC02050 RNA expression in tumor versus normal tissue (log2 FC = +0.120, t-test p < 0.001).
This table shows molecular features associated with LINC02050 in patient tissues and cancer cell lines. In patient samples, LINC02050 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
